Astatine (BioDeep_00000843980)
代谢物信息卡片
Astatine
化学式: At2 (420)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: [At][At]
InChI: InChI=1S/At2/c1-2
数据库引用编号
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Hiroyuki Suzuki, Yuta Kaizuka, Maho Tatsuta, Hiroshi Tanaka, Nana Washiya, Yoshifumi Shirakami, Kazuhiro Ooe, Atsushi Toyoshima, Tadashi Watabe, Takahiro Teramoto, Ichiro Sasaki, Shigeki Watanabe, Noriko S Ishioka, Jun Hatazawa, Tomoya Uehara, Yasushi Arano. Neopentyl Glycol as a Scaffold to Provide Radiohalogenated Theranostic Pairs of High In Vivo Stability.
Journal of medicinal chemistry.
2021 11; 64(21):15846-15857. doi:
10.1021/acs.jmedchem.1c01147. [PMID: 34708646] - Yawen Li, Ming-Kuan Chyan, Donald K Hamlin, Holly Nguyen, Robert Vessella, D Scott Wilbur. Evaluation of radioiodinated protein conjugates and their potential metabolites containing lysine-urea-glutamate (LuG), PEG and closo-decaborate(2-) as models for targeting astatine-211 to metastatic prostate cancer.
Nuclear medicine and biology.
2021 01; 92(?):217-227. doi:
10.1016/j.nucmedbio.2020.04.005. [PMID: 32409263] - Yasuhiro Ohshima, Hiroyuki Suzuki, Hirofumi Hanaoka, Ichiro Sasaki, Shigeki Watanabe, Hiromitsu Haba, Yasushi Arano, Yoshito Tsushima, Noriko S Ishioka. Preclinical evaluation of new α-radionuclide therapy targeting LAT1: 2-[211At]astato-α-methyl-L-phenylalanine in tumor-bearing model.
Nuclear medicine and biology.
2020 Nov; 90-91(?):15-22. doi:
10.1016/j.nucmedbio.2020.08.003. [PMID: 32916470] - Noboru Oriuchi, Miho Aoki, Naoyuki Ukon, Kohshin Washiyama, Chengbo Tan, Saki Shimoyama, Ken-Ichi Nishijima, Kazuhiro Takahashi, Hiroshi Ito, Takayuki Ikezoe, Songji Zhao. Possibility of cancer-stem-cell-targeted radioimmunotherapy for acute myelogenous leukemia using 211At-CXCR4 monoclonal antibody.
Scientific reports.
2020 04; 10(1):6810. doi:
10.1038/s41598-020-63557-9. [PMID: 32321944] - Miho Aoki, Songji Zhao, Kazuhiro Takahashi, Kohshin Washiyama, Naoyuki Ukon, Chengbo Tan, Saki Shimoyama, Ken-Ichi Nishijima, Kazuma Ogawa. Preliminary Evaluation of Astatine-211-Labeled Bombesin Derivatives for Targeted Alpha Therapy.
Chemical & pharmaceutical bulletin.
2020; 68(6):538-545. doi:
10.1248/cpb.c20-00077. [PMID: 32475858] - Yana Dekempeneer, Tom Bäck, Emma Aneheim, Holger Jensen, Janik Puttemans, Catarina Xavier, Marleen Keyaerts, Stig Palm, Per Albertsson, Tony Lahoutte, Vicky Caveliers, Sture Lindegren, Matthias D'Huyvetter. Labeling of Anti-HER2 Nanobodies with Astatine-211: Optimization and the Effect of Different Coupling Reagents on Their in Vivo Behavior.
Molecular pharmaceutics.
2019 08; 16(8):3524-3533. doi:
10.1021/acs.molpharmaceut.9b00354. [PMID: 31268724] - Christoph Denk, Martin Wilkovitsch, Emma Aneheim, Matthias M Herth, Holger Jensen, Sture Lindegren, Hannes Mikula. Multifunctional Clickable Reagents for Rapid Bioorthogonal Astatination and Radio-Crosslinking.
ChemPlusChem.
2019 07; 84(7):775-778. doi:
10.1002/cplu.201900114. [PMID: 31681526] - James M Kelly, Alejandro Amor-Coarasa, Anastasia Nikolopoulou, Till Wüstemann, Peter Barelli, Dohyun Kim, Clarence Williams, Xiwei Zheng, Cong Bi, Bao Hu, J David Warren, David S Hage, Stephen G DiMagno, John W Babich. Dual-Target Binding Ligands with Modulated Pharmacokinetics for Endoradiotherapy of Prostate Cancer.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
2017 09; 58(9):1442-1449. doi:
10.2967/jnumed.116.188722. [PMID: 28450562] - Huizi Keiko Li, Yukie Morokoshi, Kotaro Nagatsu, Tadashi Kamada, Sumitaka Hasegawa. Locoregional therapy with α-emitting trastuzumab against peritoneal metastasis of human epidermal growth factor receptor 2-positive gastric cancer in mice.
Cancer science.
2017 Aug; 108(8):1648-1656. doi:
10.1111/cas.13282. [PMID: 28514062] - Britta Langen, Nils Rudqvist, Khalil Helou, Eva Forssell-Aronsson. Microarray Studies on 211At Administration in BALB/c Nude Mice Indicate Systemic Effects on Transcriptional Regulation in Nonthyroid Tissues.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
2017 02; 58(2):346-353. doi:
10.2967/jnumed.116.176958. [PMID: 27765860] - Elin Cederkrantz, Håkan Andersson, Peter Bernhardt, Tom Bäck, Ragnar Hultborn, Lars Jacobsson, Holger Jensen, Sture Lindegren, Michael Ljungberg, Tobias Magnander, Stig Palm, Per Albertsson. Absorbed Doses and Risk Estimates of (211)At-MX35 F(ab')2 in Intraperitoneal Therapy of Ovarian Cancer Patients.
International journal of radiation oncology, biology, physics.
2015 Nov; 93(3):569-76. doi:
10.1016/j.ijrobp.2015.07.005. [PMID: 26460999] - Marek Pruszyński, Monika Łyczko, Aleksander Bilewicz, Michael R Zalutsky. Stability and in vivo behavior of Rh[16aneS4-diol]211 at complex: a potential precursor for astatine radiopharmaceuticals.
Nuclear medicine and biology.
2015 May; 42(5):439-445. doi:
10.1016/j.nucmedbio.2014.12.011. [PMID: 25687450] - Holisoa Rajerison, François Guérard, Marie Mougin-Degraef, Mickael Bourgeois, Isidro Da Silva, Michel Chérel, Jacques Barbet, Alain Faivre-Chauvet, Jean-François Gestin. Radioiodinated and astatinated NHC rhodium complexes: synthesis.
Nuclear medicine and biology.
2014 May; 41 Suppl(?):e23-9. doi:
10.1016/j.nucmedbio.2013.12.004. [PMID: 24661351] - Johnnie J Orozco, Tom Bäck, Aimee Kenoyer, Ethan R Balkin, Donald K Hamlin, D Scott Wilbur, Darrell R Fisher, Shani L Frayo, Mark D Hylarides, Damian J Green, Ajay K Gopal, Oliver W Press, John M Pagel. Anti-CD45 radioimmunotherapy using (211)At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model.
Blood.
2013 May; 121(18):3759-67. doi:
10.1182/blood-2012-11-467035. [PMID: 23471305] - Elin Cederkrantz, Eva Angenete, Tom Bäck, Peter Falk, Börje Haraldsson, Marie-Louise Ivarsson, Holger Jensen, Sture Lindegren, Ragnar Hultborn, Lars Jacobsson. Evaluation of effects on the peritoneum after intraperitoneal α-radioimmunotherapy with (211)At.
Cancer biotherapy & radiopharmaceuticals.
2012 Aug; 27(6):353-64. doi:
10.1089/cbr.2012.1184. [PMID: 22690847] - A Sabatié-Gogova, J Champion, S Huclier, N Michel, F Pottier, N Galland, Z Asfari, M Chérel, G Montavon. Characterization of At- species in simple and biological media by high performance anion exchange chromatography coupled to gamma detector.
Analytica chimica acta.
2012 Apr; 721(?):182-8. doi:
10.1016/j.aca.2012.01.052. [PMID: 22405318] - D Scott Wilbur, Ming-Kuan Chyan, Hirohisa Nakamae, Yun Chen, Donald K Hamlin, Erlinda B Santos, Brian T Kornblit, Brenda M Sandmaier. Reagents for astatination of biomolecules. 6. An intact antibody conjugated with a maleimido-closo-decaborate(2-) reagent via sulfhydryl groups had considerably higher kidney concentrations than the same antibody conjugated with an isothiocyanato-closo-decaborate(2-) reagent via lysine amines.
Bioconjugate chemistry.
2012 Mar; 23(3):409-20. doi:
10.1021/bc200401b. [PMID: 22296587] - Sofia Helena Linnea Frost, Tom Bäck, Nicolas Chouin, Holger Jensen, Ragnar Hultborn, Lars Jacobsson, Sture Lindegren. In vivo distribution of avidin-conjugated MX35 and (211)At-labeled, biotinylated poly-L-lysine for pretargeted intraperitoneal α-radioimmunotherapy.
Cancer biotherapy & radiopharmaceuticals.
2011 Dec; 26(6):727-36. doi:
10.1089/cbr.2011.1046. [PMID: 22087606] - D Scott Wilbur, Ming-Kuan Chyan, Donald K Hamlin, Holly Nguyen, Robert L Vessella. Reagents for astatination of biomolecules. 5. Evaluation of hydrazone linkers in (211)At- and (125)I-labeled closo-decaborate(2-) conjugates of Fab' as a means of decreasing kidney retention.
Bioconjugate chemistry.
2011 Jun; 22(6):1089-102. doi:
10.1021/bc1005625. [PMID: 21513347] - Almut Walte, S Sriyapureddy, D Krull, T Petrich, G-J Meyer, W H Knapp. (211)At-antiCD33 in NMRI nu/nu mice. Biodistribution, in vivo stability and radiotoxicity.
Nuklearmedizin. Nuclear medicine.
2011; 50(5):214-20. doi:
10.3413/nukmed-0385-11-02. [PMID: 21789339] - Tom Bäck, Börje Haraldsson, Ragnar Hultborn, Holger Jensen, Martin E Johansson, Sture Lindegren, Lars Jacobsson. Glomerular filtration rate after alpha-radioimmunotherapy with 211At-MX35-F(ab')2: a long-term study of renal function in nude mice.
Cancer biotherapy & radiopharmaceuticals.
2009 Dec; 24(6):649-58. doi:
10.1089/cbr.2009.0628. [PMID: 20025544] - Håkan Andersson, Elin Cederkrantz, Tom Bäck, Chaitanya Divgi, Jörgen Elgqvist, Jakob Himmelman, György Horvath, Lars Jacobsson, Holger Jensen, Sture Lindegren, Stig Palm, Ragnar Hultborn. Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2--a phase I study.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
2009 Jul; 50(7):1153-60. doi:
10.2967/jnumed.109.062604. [PMID: 19525452] - D Scott Wilbur, Ming-Kuan Chyan, Donald K Hamlin, Matthew A Perry. Reagents for astatination of biomolecules. 3. Comparison of closo-decaborate(2-) and closo-dodecaborate(2-) moieties as reactive groups for labeling with astatine-211.
Bioconjugate chemistry.
2009 Mar; 20(3):591-602. doi:
10.1021/bc800515d. [PMID: 19236022] - Hirohisa Nakamae, D Scott Wilbur, Donald K Hamlin, Monica S Thakar, Erlinda B Santos, Darrell R Fisher, Aimee L Kenoyer, John M Pagel, Oliver W Press, Rainer Storb, Brenda M Sandmaier. Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the alpha-emitting radionuclides bismuth-213 or astatine-211.
Cancer research.
2009 Mar; 69(6):2408-15. doi:
10.1158/0008-5472.can-08-4363. [PMID: 19244101] - D Scott Wilbur, Donald K Hamlin, Ming-Kuan Chyan, Martin W Brechbiel. Streptavidin in antibody pretargeting. 5. chemical modification of recombinant streptavidin for labeling with the alpha-particle-emitting radionuclides 213Bi and 211At.
Bioconjugate chemistry.
2008 Jan; 19(1):158-70. doi:
10.1021/bc7002428. [PMID: 18072725] - Almut Walte, Siva Sankar Reddy Sriyapureddy, Zekiye Korkmaz, Doris Krull, Oliver Bolte, Michael Hofmann, Geerd-J Meyer, Wolfram H Knapp. Preparation and evaluation of 211At labelled antineoplastic antibodies.
Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.
2007; 10(2):277s-285s. doi:
NULL. [PMID: 17718931] - Natasha E Fullerton, Marie Boyd, Susan C Ross, Sally L Pimlott, John Babich, David Kirk, Michael R Zalutsky, Robert J Mairs. Comparison of radiohaloanalogues of meta-iodobenzylguanidine (MIBG) for a combined gene- and targeted radiotherapy approach to bladder carcinoma.
Medicinal chemistry (Shariqah (United Arab Emirates)).
2005 Nov; 1(6):611-8. doi:
10.2174/157340605774598090. [PMID: 16787344] - Marie Boyd, Robert J Mairs, W Nicol Keith, Susan C Ross, Philip Welsh, Gamal Akabani, Jonathan Owens, Ganesan Vaidyanathan, Ross Carruthers, Jennifer Dorrens, Michael R Zalutsky. An efficient targeted radiotherapy/gene therapy strategy utilising human telomerase promoters and radioastatine and harnessing radiation-mediated bystander effects.
The journal of gene medicine.
2004 Aug; 6(8):937-47. doi:
10.1002/jgm.578. [PMID: 15293352] - J Bredow, M Kretzschmar, G Wunderlich, W Dörr, T Pohl, W-G Franke, J Kotzerke. [Therapy of malignant ascites in vivo by 211At-labelled microspheres].
Nuklearmedizin. Nuclear medicine.
2004 Mar; 43(2):63-8. doi:
10.1267/nukl04020063. [PMID: 15029267] - Sture Lindegren, Börje Karlsson, Lars Jacobsson, Håkan Andersson, Ragnar Hultborn, Gunnar Skarnemark. (211)At-labeled and biotinylated effector molecules for pretargeted radioimmunotherapy using poly-L- and poly-D-Lysine as multicarriers.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2003 Sep; 9(10 Pt 2):3873S-9S. doi:
NULL. [PMID: 14506185] - Anna Orlova, Johanna Höglund, Mark Lubberink, Ondrej Lebeda, Lars Gedda, Hans Lundqvist, Vladimir Tolmachev, Anders Sundin. Comparative biodistribution of the radiohalogenated (Br, I and At) antibody A33. Implications for in vivo dosimetry.
Cancer biotherapy & radiopharmaceuticals.
2002 Aug; 17(4):385-96. doi:
10.1089/108497802760363187. [PMID: 12396703] - A T Yordanov, K Garmestani, M Zhang, Z Zhang, Z Yao, K E Phillips, B Herring, E Horak, M P Beitzel, U P Schwarz, O A Gansow, P S Plascjak, W C Eckelman, T A Waldmann, M W Brechbiel. Preparation and in vivo evaluation of linkers for 211At labeling of humanized anti-Tac.
Nuclear medicine and biology.
2001 Oct; 28(7):845-56. doi:
10.1016/s0969-8051(01)00257-8. [PMID: 11578907] - S Demartis, L Tarli, L Borsi, L Zardi, D Neri. Selective targeting of tumour neovasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectin.
European journal of nuclear medicine.
2001 Apr; 28(4):534-9. doi:
10.1007/s002590100480. [PMID: 11357506] - T E Wheldon, R J Mairs, M Boyd. Genetic enhancement of radionuclide cancer therapy.
Lancet (London, England).
1999 Dec; 354(9194):1999-2000. doi:
10.1016/s0140-6736(05)76773-8. [PMID: 10622325] - K M Murud, R H Larsen, P Hoff, M R Zalutsky. Synthesis, purification, and in vitro stability of 211At- and 125I-labeled amidobisphosphonates.
Nuclear medicine and biology.
1999 May; 26(4):397-403. doi:
10.1016/s0969-8051(98)00119-x. [PMID: 10382843] - C F Foulon, K L Alston, M R Zalutsky. Astatine-211-labeled biotin conjugates resistant to biotinidase for use in pretargeted radioimmunotherapy.
Nuclear medicine and biology.
1998 Feb; 25(2):81-8. doi:
10.1016/s0969-8051(97)00166-2. [PMID: 9468020] - G Wunderlich, W G Franke, I Doberenz, S Fischer. Two ways to establish potential At-211 radiopharmaceuticals.
Anticancer research.
1997 May; 17(3B):1809-13. doi:
NULL. [PMID: 9179238] - C F Foulon, B W Schoultz, M R Zalutsky. Preparation and biological evaluation of an astatine-211 labeled biotin conjugate: biotinyl-3-[211 At]astatoanilide.
Nuclear medicine and biology.
1997 Feb; 24(2):135-43. doi:
10.1016/s0969-8051(96)00185-0. [PMID: 9089706] - R H Larsen, O S Bruland, P Hoff, J Alstad, T Lindmo, E K Rofstad. Inactivation of human osteosarcoma cells in vitro by 211At-TP-3 monoclonal antibody: comparison with astatine-211-labeled bovine serum albumin, free astatine-211 and external-beam X rays.
Radiation research.
1994 Aug; 139(2):178-84. doi:
10.2307/3578662. [PMID: 8052693] - R H Larsen, O S Bruland, P Hoff, J Alstad, E K Rofstad. Analysis of the therapeutic gain in the treatment of human osteosarcoma microcolonies in vitro with 211At-labelled monoclonal antibody.
British journal of cancer.
1994 Jun; 69(6):1000-5. doi:
10.1038/bjc.1994.196. [PMID: 8198960] - D S Wilbur, R L Vessella, J E Stray, D K Goffe, K A Blouke, R W Atcher. Preparation and evaluation of para-[211At]astatobenzoyl labeled anti-renal cell carcinoma antibody A6H F(ab')2. In vivo distribution comparison with para-[125I]iodobenzoyl labeled A6H F(ab')2.
Nuclear medicine and biology.
1993 Nov; 20(8):917-27. doi:
10.1016/0969-8051(93)90092-9. [PMID: 8298571] - G Wunderlich, E Henke, B Iwe, W G Franke, S Fischer, R Dreyer. Animal studies on the in vivo stability of 211At-labelled albumin particles.
Nuclear medicine communications.
1986 Apr; 7(4):211-4. doi:
10.1097/00006231-198604000-00002. [PMID: 3725235] - T C Richardson. Astatine (211At) as a therapeutic radionuclide. The plasma:blood cell distribution in vitro.
International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.
1986; 13(5):583-4. doi:
10.1016/0883-2897(86)90142-x. [PMID: 3818324] - A Harrison, L Royle. Determination of absorbed dose to blood, kidneys, testes and thyroid in mice injected with 211At and comparison of testes mass and sperm number in x-irradiated and 211At treated mice.
Health physics.
1984 Feb; 46(2):377-83. doi:
10.1097/00004032-198402000-00013. [PMID: 6693268] - A T Vaughan, W J Bateman, D R Fisher. The in vivo fate of a 211At labelled monoclonal antibody with known specificity in a murine system.
International journal of radiation oncology, biology, physics.
1982 Nov; 8(11):1943-6. doi:
10.1016/0360-3016(82)90453-9. [PMID: 6295988] - A T Vaughan, W J Bateman, G Brown, J Cowan. The specific inhibition of cellular clonogenic proliferation using 211At labelled lectins and antibodies--I.
International journal of nuclear medicine and biology.
1982; 9(3):167-71. doi:
10.1016/0047-0740(82)90091-2. [PMID: 6957405] - A M Friedman, M R Zalutsky, W Wung, F Buckingham, G H Scherr, B Wainer, R L Hunter, E H Appelman, R M Rothberg, F W Fitch, F P Stuart, S J Simonian. Preparation of a biologically stable and immunogenically competent astatinated protein.
International journal of nuclear medicine and biology.
1977 Dec; 4(3-4):219-24. doi:
10.1016/0047-0740(77)90146-2. [PMID: 608810] - J A Myburgh, J A Smit. Enhancement and antigen suicide in the outbred primate.
Transplantation proceedings.
1973 Mar; 5(1):597-600. doi:
NULL. [PMID: 4633092] - N D Eckhoff, R W Clack, H D Anthony, A P Gray. Measurement of toxic heavy metals by neutron activation analysis.
Toxicology and applied pharmacology.
1973 Feb; 24(2):178-81. doi:
10.1016/0041-008x(73)90137-3. [PMID: 4696302]